Tissue factor (TF) on circulating microparticles has recently received much attention as a factor in myocardial infarction. We have developed systems by which we have been able to investigate the thrombogenic potential of blood-borne TF. Thrombi develop when native human blood is passed over either collagen-coated glass slides or over pig arterial media. These thrombi immunostain for TF even when the substrate contains none. Moreover, we have demonstrated that the deposited TF is active because the thrombi contain fibrin; fibrin deposition and thrombotic mass are both inhibited by the inclusion of a potent TF-inhibitor in the perfusions. We have also shown that leukocyte-derived particles attach to platelets in a reaction mediated by adhesion proteins.
No takes yet. Share an insight, caveat, or question.
Rauch et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: